---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-010535"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2022-05-24T23:59:59+00:00"
generated_at: "2026-06-25T07:38:20.500179+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director and Head of Strategic Partnerships Saiid Zarrabian departs Kintara; receives $213,750 severance

## Summary
- Zarrabian steps down from Board and Head of Strategic Partnerships effective May 23, 2022 by mutual agreement, not due to disagreements.
- Severance includes nine months base salary totaling $213,750 paid in installments, plus $24,826.67 one-time bonus.
- Stock options accelerated: 2,517,713 vested (including 6 months service credit); 754,188 unvested options forfeited.
- Healthcare and life insurance premiums reimbursed for up to nine months; non-solicitation covenant applies for 12 months.

## SEC filing metadata
- accession: 0000950170-22-010535
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2022-05-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017022010535/0000950170-22-010535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017022010535/ktra-20220520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-010535
- JSON: https://secwatch.observer/filing/0000950170-22-010535.json
- Plain text: https://secwatch.observer/filing/0000950170-22-010535.txt

## Key facts
- Executive change
  Saiid Zarrabian departed as Head of Strategic Partnerships and Director at TuHURA Biosciences, Inc./NV.
  - Action: stepped down
  - Role: Head of Strategic Partnerships and Director
  source text: On May 20, 2022, Kintara Therapeutics, Inc. (the “Company”) and Saiid Zarrabian, the Company’s Head of Strategic Partnerships and a member of the Board of Directors (the “Board”) of the Company, mutually agreed that Mr. Zarrabian would step down from his role as Head of Strategic Partnerships and as a member of the Board, effective as of May 23, 2022 (the “Separation Date”) to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017022010535/0000950170-22-010535-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.